Cover - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Mar. 31, 2025 |
Jun. 30, 2024 |
|
| Document Information [Line Items] | |||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Interactive Data Current | Yes | ||
| ICFR Auditor Attestation Flag | false | ||
| Amendment Flag | true | ||
| Amendment Description | On March 31, 2025, 180 Life Sciences Corp. (“180 Life,” the “Company,” “we,” “us,” or “our”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Form 10-K”) with the U.S. Securities and Exchange Commission (the “SEC”). The Original Form 10-K omitted certain disclosures under Part III, Items 10, 11, 12, 13 and 14 of Form 10-K in reliance on General Instruction G(3) to Form 10-K, which provides that such information may be either incorporated by reference from the registrant’s definitive proxy statement or included in an amendment to Form 10-K, in either case filed with the SEC not later than 120 days after the end of the fiscal year. Subsequently, on April 25, 2025, the Company filed an Amendment No. 1 to Annual Report on Form 10-K with the SEC to include such omitted information (“Amendment No. 1”).Amendment No. 1 failed to include certain required XBRL tagging and this Amendment No. 2 to Annual Report on Form 10-K is being filed solely to include such XBRL tagging under Item 10. Directors, Executive Officers and Corporate Governance.As such, this Amendment No. 2: ●restates Part III, Item 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), of Amendment No. 1 to include the required XBRL tagging; and ●files new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment under Item 15 of Part IV hereof, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Amendment No. 2 does not otherwise change or update any of the disclosures set forth in the Original Form 10-K, as amended by Amendment No. 1, and, except as expressly stated herein, does not reflect events occurring after the filing of the Original Form 10-K.Unless the context requires otherwise, references to the “Company,” “we,” “us,” “our,” “180 Life”, “180LS” and “180 Life Sciences Corp.” refer specifically to 180 Life Sciences Corp. and its consolidated subsidiaries. References to “KBL” refer to the Company prior to our November 6, 2020 Business Combination.In addition, unless the context otherwise requires and for the purposes of this Report only: ●“180” refers to 180 Life Corp. (f/k/a 180 Life Sciences Corp.), our wholly-owned subsidiary. “Business Combination” means that certain business combination which closed on November 6, 2020, between KBL, KBL Merger Sub, Inc. (“Merger Sub”), 180, Katexco Pharmaceuticals Corp. (“Katexco”), CannBioRex Pharmaceuticals Corp. (“CBR Pharma”), 180 Therapeutics L.P. (“180 LP” and together with Katexco and CBR Pharma, the “180 Subsidiaries” and, together with 180 Life Sciences Corp., the “180 Parties”), and Lawrence Pemble, in his capacity as representative of the stockholders of the 180 Parties, whereby KBL acquired the 180 Subsidiaries. ●“CAD” refers to Canadian dollars; ●“Exchange Act” refers to the Securities Exchange Act of 1934, as amended; ●“£” or “GBP” refers to British pounds sterling; ●“SEC” or the “Commission” refers to the United States Securities and Exchange Commission; and ●“Securities Act” refers to the Securities Act of 1933, as amended. | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Documents Incorporated by Reference [Text Block] | None | ||
| Entity Information [Line Items] | |||
| Entity Registrant Name | 180 LIFE SCIENCES CORP. | ||
| Entity Central Index Key | 0001690080 | ||
| Entity File Number | 001-38105 | ||
| Entity Tax Identification Number | 90-1890354 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Shell Company | false | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Public Float | $ 1,548,662 | ||
| Entity Contact Personnel [Line Items] | |||
| Entity Address, Address Line One | 3000 El Camino Real, Bldg. 4 | ||
| Entity Address, Address Line Two | Suite 200 | ||
| Entity Address, City or Town | Palo Alto | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94306 | ||
| Entity Phone Fax Numbers [Line Items] | |||
| City Area Code | (650) | ||
| Local Phone Number | 507-0669 | ||
| Entity Listings [Line Items] | |||
| Entity Common Stock, Shares Outstanding | 5,185,780 | ||
| Common Stock, par value $0.0001 per share | |||
| Entity Listings [Line Items] | |||
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
| Trading Symbol | ATNF | ||
| Security Exchange Name | NASDAQ | ||
| Warrants to purchase shares of Common Stock | |||
| Entity Listings [Line Items] | |||
| Title of 12(b) Security | Warrants to purchase shares of Common Stock | ||
| Trading Symbol | ATNFW | ||
| Security Exchange Name | NASDAQ |